Stock listing

ASX:IMC Immuron Limited Share Price

Home listing (ASX) of Immuron Limited

Follow Immuron Limited into a list and get an email when it puts out news.

Share price · ASX:IMC

$0.037 AUD 0.000 (0.0%)

Close on Nov 20, 2026

Past year -42.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.037 – $0.040 AUDNov 20, 2026
Volume
984,625 sharesNov 20, 2026
Market cap
$11.95M AUDAt the close on Nov 20, 2026 · price × 322.8M shares outstanding
52-week range
$0.026 – $0.074 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$19,780 AUDMedian day 26,145 shares · 22 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Immuron Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:IMC · Home$0.037 AUD0.000 (0.0%)984,625$0.040$0.040$0.037$0.037Close on Nov 20, 2026
NASDAQ:IMRN$0.90 USD+0.05 (+5.9%)19,678$0.85$0.90$0.815$0.85Close on Nov 20, 2026
Frankfurt:ANW€0.017 EUR0.000 (0.0%)—€0.017€0.017€0.017€0.017Close on Nov 19, 2026
Munich:ANW€0.027 EUR0.000 (0.0%)—€0.027€0.027€0.027€0.027Close on Nov 20, 2026
Frankfurt:ANWA€0.66 EUR-0.085 (-11.4%)—€0.72€0.72€0.66€0.745Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:IMC · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0370.0000.0%$0.040$0.040$0.037984,625
$0.0370.0000.0%$0.034$0.039$0.033668,139
$0.0370.0000.0%$0.037$0.037$0.0370
$0.0370.0000.0%$0.037$0.037$0.0370
$0.0370.0000.0%$0.037$0.037$0.0370
$0.0370.0000.0%$0.037$0.037$0.0370
$0.037+0.003+8.8%$0.036$0.037$0.03629,218
$0.0340.0000.0%$0.034$0.034$0.0340
$0.0340.0000.0%$0.034$0.034$0.0340
$0.034-0.001-2.9%$0.033$0.034$0.033134,594
$0.035-0.005-12.5%$0.035$0.035$0.033220,762
$0.0400.0000.0%$0.040$0.040$0.0400
$0.0400.0000.0%$0.040$0.040$0.0400
$0.0400.0000.0%$0.040$0.040$0.0400
$0.0400.0000.0%$0.040$0.040$0.0400
$0.0400.0000.0%$0.040$0.040$0.0400
$0.040+0.008+25.0%$0.041$0.041$0.0402,611
$0.032-0.005-13.5%$0.038$0.038$0.032125,890
$0.037-0.003-7.5%$0.039$0.039$0.036591,677
$0.0400.0000.0%$0.040$0.040$0.0400
$0.0400.0000.0%$0.040$0.040$0.0400
$0.0400.0000.0%$0.040$0.040$0.04023,846
$0.0400.0000.0%$0.040$0.040$0.0400
$0.040+0.006+17.6%$0.036$0.040$0.036657,877
$0.0340.0000.0%$0.034$0.034$0.0340
$0.034-0.002-5.6%$0.035$0.035$0.03437,075
$0.036-0.002-5.3%$0.038$0.038$0.036361,155
$0.038-0.004-9.5%$0.042$0.044$0.038946,098
$0.0420.0000.0%$0.042$0.042$0.04299,200
$0.042-0.003-6.7%$0.045$0.045$0.042119,973
$0.0450.0000.0%$0.045$0.045$0.0450
$0.0450.0000.0%$0.045$0.045$0.0450
$0.045+0.007+18.4%$0.040$0.045$0.04017,447
$0.038-0.002-5.0%$0.038$0.038$0.03895
$0.0400.0000.0%$0.040$0.040$0.040400,445
$0.0400.0000.0%$0.040$0.040$0.0400
$0.0400.0000.0%$0.040$0.040$0.0400
$0.040-0.005-11.1%$0.042$0.042$0.040227,950
$0.045+0.002+4.7%$0.043$0.045$0.043562,115
$0.043-0.003-6.5%$0.044$0.044$0.043901,209
$0.0460.0000.0%$0.046$0.047$0.04630,800
$0.0460.0000.0%$0.046$0.046$0.0461,000
$0.0460.0000.0%$0.046$0.046$0.0460
$0.046+0.001+2.2%$0.044$0.046$0.04420,675
$0.045-0.003-6.3%$0.047$0.047$0.044696,276
$0.048+0.002+4.3%$0.046$0.051$0.0461,211,911
$0.046+0.002+4.5%$0.044$0.046$0.043156,253
$0.0440.0000.0%$0.043$0.046$0.0431,684,179
$0.044-0.007-13.7%$0.046$0.046$0.044388,500
$0.051-0.001-1.9%$0.052$0.052$0.048360,560
$0.052-0.006-10.3%$0.055$0.055$0.052226,615
$0.058-0.003-4.9%$0.061$0.065$0.0551,357,524
$0.061+0.003+5.2%$0.058$0.064$0.0584,234,103
$0.058+0.004+7.4%$0.054$0.062$0.0483,157,469
$0.054+0.014+35.0%$0.048$0.056$0.0474,642,398
$0.040+0.003+8.1%$0.041$0.044$0.040935,152
$0.0370.0000.0%$0.037$0.037$0.03715,251
$0.037-0.002-5.1%$0.038$0.038$0.037212,178
$0.039+0.001+2.6%$0.039$0.039$0.039273
$0.038+0.001+2.7%$0.039$0.041$0.03881,766
$0.0370.0000.0%$0.037$0.037$0.0370
$0.037-0.005-11.9%$0.042$0.042$0.03726,145
$0.042+0.005+13.5%$0.036$0.042$0.036145,506
$0.0370.0000.0%$0.037$0.037$0.0370
$0.037+0.003+8.8%$0.037$0.037$0.0373,774
$0.034-0.001-2.9%$0.034$0.034$0.0348,300
$0.035-0.002-5.4%$0.035$0.035$0.0358,300

Splits

1 split · ASX:IMC · every price before a split is adjusted for it

DayRatioWhat
1-for-40Consolidation
Ticker
ASX:IMC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
ASX
Currency
AUD

What changed lately

Latest news

Results of Annual General Meeting

Nov 18, 2026

Closed $0.037 (0.0%) on Nov 19, 2026

CEO Address

Nov 17, 2026

Closed $0.037 (0.0%) on Nov 18, 2026

Immuron Engages LifeSci Capital

Nov 10, 2026

Closed $0.034 (0.0%) on Nov 11, 2026

Emerging Growth Conference Presentation

Oct 28, 2026

Closed $0.04 (+25.0%) on Oct 29, 2026

Immuron FY27 Sales Update

Oct 26, 2026

Closed $0.037 (-7.5%) on Oct 27, 2026

Travelan Phase 2 Study Results Published

Oct 12, 2026

Closed $0.042 (0.0%) on Oct 13, 2026

All Immuron Limited news

Immuron Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
36 in the last 12 months · 201 in all · newest Nov 18, 2026 · oldest 2016
Decks
112 decks · latest Nov 18, 2026

Where Immuron Limited is listed

ListingExchangeCountryCurrency
ASX:IMC · Home listing · This pageASXAustraliaAUD
NASDAQ:IMRNNASDAQUnited StatesUSD
gettex:ANWgettexGermanyEUR
Frankfurt:ANWFrankfurtGermanyEUR
BOATS:IMRNBOATSUnited StatesUSD
Munich:ANWMunichGermanyEUR
Munich:ANWAMunichGermanyEUR
Stuttgart:ANWStuttgartGermanyEUR
Dusseldorf:ANWADusseldorfGermanyEUR
Frankfurt:ANWAFrankfurtGermanyEUR
gettex:ANWAgettexGermanyEUR
Lang & Schwarz:A2DTD8Lang & SchwarzGermanyEUR
LS Exchange:A2DTD8LS ExchangeGermanyEUR
Stuttgart:ANWAStuttgartGermanyEUR
Tradegate:ANWATradegateGermanyEUR

Valuation

EV/sales 0.4× against a median of 5.4×: 2nd lowest of 3 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$2.93M AUD
P/E
Loss
EV/sales
0.4×
EV/EBITDA
Negative EBITDA
Price/book
1.1×
Gross margin
64.5%
Operating margin
−61.4%
Net margin
−49.8%
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Immuron Limited · ASX:IMCUS$7.91MUS$1.94Mn/a0.4×n/a1.1×−49.8%0.0×n/a
Moleculin Biotech, Inc. · NASDAQ:MBRXUS$8.22MUS$1.04Mn/an/an/a0.6×n/a0.0×0.42
IN8bio, Inc. · NASDAQ:INABUS$8.19M−US$3.03Mn/an/an/a0.6×n/a0.2×1.25
Intensity Therapeutics, Inc. · NASDAQ:INTSUS$8.19M−US$220,086n/an/an/a1.1×n/a0.0×1.30
Palatin Technologies, Inc. · AMEX:PTNUS$8.16MUS$4.58Mn/a12.7×n/a4.0×n/a0.1×0.61
Dare Bioscience, Inc. · NASDAQ:DAREUS$8.01M−US$2.65Mn/a−1.9×n/a3.4×−749.8%0.4×1.34
Cellectar Biosciences, Inc. · NASDAQ:CLRBUS$8.00M−US$15.05Mn/an/an/a0.4×n/a0.1×1.71
Phio Pharmaceuticals Corp. · NASDAQ:PHIOUS$7.84M−US$2.77Mn/an/an/a0.9×n/a0.0×1.24
Vivesto AB · OMXSTO:VIVEUS$7.77MUS$6.13Mn/an/an/a0.5×n/a0.0×n/a
Annexin Pharmaceuticals AB · OMXSTO:ANNXUS$7.60MUS$6.18Mn/an/an/a6.3×n/a0.0×n/a
Solvonis Therapeutics PLC · LSE:SVNSUS$7.57MUS$6.80Mn/an/an/a1.2×n/a0.0×n/a
Median of the othersUS$8.01MUS$408,0905.4×1.0×−749.8%0.0×1.25

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
0.29 AUD · Analysts' mean
Revenue, year to Jun 2027
8.64M · 1 analyst

Team and board

Officers

OfficerRole
Steven LydeamoreChief Executive Officer
Aaron LauritaChief Financial Officer
Olga SmejkalovaCompany Secretary
Flavio PalumboChief Commercial Officer
Jerry KanellosChief Scientific Officer
Joanne CaseyResearch & Development Manager

Board

DirectorRole
Paul BrennanChairman
Daniel PollockNon-Executive Director – LL.B. Dip.L.P.
Jeannie JoughinNon-Executive Director – BSc (Hons), PhD, MAICD
Ravi SavarirayanNon-Executive Director

Events

QuarterResultsShare move
Quarter to Sep 30, 2025Dec 3, 2025−1.5%
Q4 2025Aug 28, 2025 · Before open0.0%
Q3 2025May 28, 2025+14.3%
Q2 2025Feb 28, 2025−6.0%
Quarter to Sep 30, 2024Oct 16, 2024−3.5%
Q4 2024Aug 30, 2024+2.4%
Quarter to Mar 31, 2024Apr 9, 2024+13.6%
Q2 2024Feb 28, 2024+2.9%
Quarter to Sep 30, 2023Oct 11, 2023+5.3%
Q4 2023Aug 30, 2023 · Before open+1.3%
All 20 quarters
QuarterResultsShare move
Q3 2023Apr 5, 2023+14.3%
Q2 2023Feb 28, 2023 · After close+2.7%
Q1 2023Nov 30, 2022+5.1%
Q4 2022Sep 7, 2022 · Before open0.0%
Q3 2022Jun 1, 2022+5.0%
Q2 2022Feb 25, 2022+7.1%
Q1 2022Dec 1, 2021−4.2%
Q4 2021Aug 31, 2021 · After close0.0%
Q3 2021Jun 2, 20210.0%
Q2 2021Feb 25, 2021−4.4%

Open Events

Decks

DeckKindSlidesDate
Shareholder Meeting (November 2026)Shareholder meeting8 slidesNov 18, 2026
Shareholder Meeting (November 2026)Shareholder meeting11 slidesNov 18, 2026
Emerging Growth Conference (October 2026)Conference13 slidesOct 28, 2026
Emerging Growth Conference 2026Conference16 slidesOct 28, 2026
Coffee Microcaps Conference 2026Conference15 slidesSep 22, 2026
Coffee Microcaps Conference (September 2026)Conference12 slidesSep 22, 2026
FY2026 Earnings PresentationEarnings6 slidesAug 28, 2026
Emerging Growth Conference (August 2026)Conference14 slidesAug 19, 2026
Emerging Growth Conference (August 2026)Conference11 slidesAug 19, 2026
TechKnow Invest Roadshow (July 2026)Conference14 slidesJul 27, 2026
Show 50 decks
DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck11 slidesJul 27, 2026
Kalkine Media Webinar (July 2026)Conference17 slidesJul 20, 2026
Investor Presentation (July 2026)Investor deck14 slidesJul 20, 2026
Emerging Growth Conference (May 2026)Conference15 slidesMay 8, 2026
Coffee Microcaps Conference (March 2026)Conference16 slidesMar 5, 2026
Coffee Microcaps Conference (March 2026)Conference13 slidesMar 5, 2026
HY26 Earnings PresentationEarnings13 slidesMar 2, 2026
Emerging Growth Conference January 2026Conference11 slidesJan 23, 2026
Emerging Growth Conference January 2026Conference8 slidesJan 23, 2026
Shareholder Meeting (November 2025)Shareholder meeting10 slidesNov 12, 2025
Emerging Growth Conference 2025Conference17 slidesOct 23, 2025
Emerging Growth Conference (October 2025)Conference14 slidesOct 23, 2025
AusBiotech Invest 2025 ConferenceConference17 slidesOct 21, 2025
AusBiotech Invest 2025Conference14 slidesOct 21, 2025
Coffee Microcaps VIP Conference 2025Conference21 slidesSep 16, 2025
Coffee Microcaps Conference (September 2025)Conference18 slidesSep 16, 2025
FY2025 Earnings PresentationEarnings13 slidesAug 29, 2025
Coffee Microcaps Conference (July 2025)Conference19 slidesJul 25, 2025
Coffee Microcaps Conference 2025Conference15 slidesMar 7, 2025
Coffee Microcaps (March 2025)Conference12 slidesMar 7, 2025
Emerging Growth Conference February 2025Conference16 slidesFeb 19, 2025
Emerging Growth Conference 18 February 2025Conference13 slidesFeb 19, 2025
21st Virtual Investor Summit Microcap Event (November 2024)Conference16 slidesNov 22, 2024
21st Virtual Investor Summit Microcap Event (November 2024)Conference19 slidesNov 22, 2024
Shareholder Meeting (November 2024)Shareholder meeting16 slidesNov 18, 2024
Shareholder Meeting (November 2024)Shareholder meeting19 slidesNov 18, 2024
Coffee Microcaps (October 2024)Conference13 slidesOct 22, 2024
Maxim Virtual Healthcare Conference 2024Conference11 slidesOct 16, 2024
Emerging Growth Conference (September 2024)Conference18 slidesSep 26, 2024
Emerging Growth Conference (September 2024)Conference30 slidesSep 26, 2024
Peak Biotech Showcase 2024Conference16 slidesAug 21, 2024
Peak Biotech Showcase 2024Conference14 slidesAug 21, 2024
MarketOpen Direct Connect Webinar (August 2024)Conference18 slidesAug 9, 2024
MarketOpen Direct Connect webinar (August 2024)Conference21 slidesAug 8, 2024
TechKnow Invest Roadshow 2024Conference15 slidesJul 31, 2024
Emerging Growth Conference (July 2024)Conference12 slidesJul 18, 2024
Sharewise Webinar (July 2024)Conference15 slidesJul 9, 2024
Sharewise Webinar (July 2024)Conference12 slidesJul 9, 2024
Peak Asset Management Sky High Luncheon June 2024Conference12 slidesMay 31, 2024
Investor Presentation (April 2024)Investor deck13 slidesApr 23, 2024

This page holds 50 of 112 decks. Open Decks

Open Decks

Financings

RaiseDate
At-the-market programme of american Depositary Shares representing ordinary shares
Terms changed: up to US$2.01M · H.C. Wainwright & Co., LLC
Dealers: H.C. Wainwright & Co., LLC (lead)
Oct 27, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue7.71M7.29M4.90M1.80M765.2K145.8K2.52M2.02M1.46M1.40M
Cost of revenue2.74M2.52M1.57M495.6K241.7K51.1K688.8K667.4K418.7K337.5K
Gross profit4.98M4.77M3.34M1.31M523.5K94.7K1.83M1.72M1.42M1.06M
Research and development1.93M3.60M5.38M2.59M657.7K1.37M1.18M1.04M2.26M4.63M
Selling, general and administrative7.72M4.48M4.52M4.22M3.52M6.09M3.10M4.95M282.2K407.8K
Operating income-4.74M-5.34M-5.80M-3.57M-2.87M-8.38M-2.91M-4.66M-3.05M-6.72M
Depreciation and amortization42.3K49.7K46.0K48.7K26.6K43.7K44.1K5.29K5.05K4.92K
EBITDA-4.69M-5.29M-5.76M-3.52M-2.84M-8.34M-2.86M-4.65M-3.04M-6.72M
Interest expense14.7K7.30K7.58K9.65K6.18K13.8K21.6K21.6K24.2K89.7K
Income before tax-4.46M-5.22M-6.94M-3.79M-2.85M-8.38M-2.93M-4.66M-3.07M-6.80M
Income tax-623.6K-1.11M-765.0K-392.9K-257.5K-431.0K-308.2K-531.0K-1.85M-1.58M
Net income-3.84M-5.22M-6.94M-3.79M-2.85M-8.38M-2.93M-4.66M-3.07M-6.80M
Earnings per share, basic-0.01-2.26-3.04-1.66-1.25-3.79-0.02-0.03-0.02-0.08
Earnings per share, diluted-2.26-3.04-1.66-1.25-3.79

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents9.02M2.83M11.7M17.2M22.1M25.0M3.25M5.12M4.73M3.99M
Short-term investments3.04M0404.1K1.83M0
Receivables1.25M1.93M1.39M417.4K662.9K334.7K327.7K968.9K1.68M1.77M
Inventory2.27M1.77M1.58M840.0K326.6K292.5K797.7K544.3K497.9K2.34M
Current assets12.8M10.0M14.7M20.4M23.7M25.8M4.41M6.68M7.05M8.27M
Property, plant and equipment114.0K154.3K200.1K226.7K33.7K70.8K17.1K20.4K18.8K
Total assets13.0M10.1M15.5M22.0M24.9M27.1M6.20M8.56M9.24M8.29M
Accounts payable1.35M1.53M2.14M1.19M1.16M758.5K384.4K1.09M689.3K1.29M
Current liabilities1.79M1.97M2.70M2.22M1.50M1.12M516.4K1.20M803.3K1.71M
Total debt117.1K173.5K189.1K209.8K20.5K61.1K42.2K365.9K
Total liabilities1.99M2.06M2.84M2.37M1.68M1.16M558.3K1.21M803.3K1.71M
Shareholders' equity11.0M8.07M12.7M19.6M23.2M25.9M5.64M7.35M8.44M6.57M
Shares outstanding297.6M230.9M227.9M18227.6M221.1M176.4M144.7M130.0M80.1M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-3.07M-6.14M-5.88M-2.60M-3.15M-4.08M-3.15M-1.80M-3.50M-6.94M
Capital spending-4.75K-2-195-7.74K-10.0K-6.63K-864-2.05K-6.59K-5.70K
Free cash flow-3.07M-6.14M-5.88M-2.60M-3.16M-4.09M-3.15M-1.80M-3.51M-6.95M
Cash from investing3.03M-2.90M327.6K-2.62M11.7K2.57K-864-2.01K-5.32K2.69K
Cash from financing6.49M199.7K829-44.7K-42.4K26.5M1.16M2.07M4.35M8.60M
Dividends paid00000000
Share buybacks-121.8K396.8K24.0K0029.3M1.96M2.89M5.47M12.5M
Change in cash6.19M-8.84M-5.55M-5.26M-3.18M22.4M-1.99M268.6K839.1K1.66M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 18, 2026Current reportSEC
Results of Annual General MeetingNov 18, 2026Meeting outcomeASX
CEO AddressNov 17, 2026Annual reportASX
6-K · Report of a foreign issuerNov 10, 2026Current reportSEC
Immuron Engages LifeSci CapitalNov 10, 2026Other filingsASX
6-K · Report of a foreign issuerOct 28, 2026Current reportSEC
Emerging Growth Conference PresentationOct 28, 2026Other filingsASX
6-K · Report of a foreign issuerOct 27, 2026Current reportSEC
Immuron Updates At-The-Market Funding FacilityOct 26, 2026FinancingASX
Immuron FY27 Sales UpdateOct 26, 2026ResultsASX
Show 200 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerOct 23, 2026Current reportSEC
424B5 · ProspectusOct 23, 2026Offer documentSEC
6-K · Report of a foreign issuerOct 21, 2026Current reportSEC
CEO to present at Emerging Growth ConferenceOct 21, 2026Notification letterASX
6-K · Report of a foreign issuerOct 16, 2026Current reportSEC
Notice of Annual General Meeting and Proxy FormOct 15, 2026Meeting noticeASX
6-K · Report of a foreign issuerOct 13, 2026Current reportSEC
Travelan Phase 2 Study Results PublishedOct 12, 2026ResultsASX
Change in substantial holdingSep 30, 2026Ownership change noticeASX
20-F · Annual reportSep 24, 2026Annual reportSEC
6-K · Report of a foreign issuerSep 24, 2026Current reportSEC
Appendix 4G and Corporate Governance StatementSep 24, 2026Other filingsASX
Annual ReportSep 24, 2026Annual reportASX
6-K · Report of a foreign issuerSep 21, 2026Current reportSEC
Presentation to Coffee Microcaps ConferenceSep 21, 2026Other filingsASX
6-K · Report of a foreign issuerSep 3, 2026Current reportSEC
PROIBS US Distribution AgreementSep 3, 2026Operations updateASX
6-K · Report of a foreign issuerAug 28, 2026Current reportSEC
FY26 Results PresentationAug 27, 2026Other filingsASX
Appendix 4E Preliminary Final ReportAug 27, 2026ResultsASX
6-K · Report of a foreign issuerAug 18, 2026Current reportSEC
Emerging Growth Conference PresentationAug 18, 2026Other filingsASX
6-K · Report of a foreign issuerAug 12, 2026Current reportSEC
Emerging Growth ConferenceAug 12, 2026Meeting noticeASX
6-K · Report of a foreign issuerJul 27, 2026Current reportSEC
6-K · Report of a foreign issuerJul 20, 2026Current reportSEC
6-K · Report of a foreign issuerJul 20, 2026Current reportSEC
6-K · Report of a foreign issuerJul 15, 2026Current reportSEC
Immuron FY26 Sales UpdateJul 15, 2026ResultsASX
6-K · Report of a foreign issuerJul 6, 2026Current reportSEC
6-K · Report of a foreign issuerJun 29, 2026Current reportSEC
6-K · Report of a foreign issuerJun 22, 2026Current reportSEC
6-K · Report of a foreign issuerJun 18, 2026Current reportSEC
6-K · Report of a foreign issuerMay 28, 2026Current reportSEC
3 · Initial statement of ownershipMay 14, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 14, 2026Insider tradeSEC
6-K · Report of a foreign issuerMay 7, 2026Current reportSEC
3 · Initial statement of ownershipMay 4, 2026Insider tradeSEC
6-K · Report of a foreign issuerApr 30, 2026Current reportSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
6-K · Report of a foreign issuerApr 16, 2026Current reportSEC
6-K · Report of a foreign issuerApr 13, 2026Current reportSEC
6-K · Report of a foreign issuerMar 5, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 27, 2026Current reportSEC
Strategic Update and HY26 ResultsFeb 25, 2026Other filingsASX
Appendix 4D and Half Year ReportFeb 25, 2026Interim reportASX
6-K · Report of a foreign issuerFeb 17, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 12, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 9, 2026Current reportSEC
6-K · Report of a foreign issuerJan 22, 2026Current reportSEC
6-K · Report of a foreign issuerJan 20, 2026Current reportSEC
6-K · Report of a foreign issuerJan 14, 2026Current reportSEC
6-K · Report of a foreign issuerJan 12, 2026Current reportSEC
6-K · Report of a foreign issuerDec 16, 2025Current reportSEC
6-K · Report of a foreign issuerDec 15, 2025Current reportSEC
6-K · Report of a foreign issuerDec 12, 2025Current reportSEC
Uniformed Services University to Release Topline DataDec 9, 2025Operations updateASX
6-K · Report of a foreign issuerDec 9, 2025Current reportSEC
6-K · Report of a foreign issuerDec 5, 2025Current reportSEC
6-K · Report of a foreign issuerDec 4, 2025Current reportSEC
6-K · Report of a foreign issuerDec 3, 2025Current reportSEC
6-K · Report of a foreign issuerDec 3, 2025Current reportSEC
6-K · Report of a foreign issuerNov 21, 2025Current reportSEC
6-K · Report of a foreign issuerNov 12, 2025Current reportSEC
6-K · Report of a foreign issuerNov 6, 2025Current reportSEC
6-K · Report of a foreign issuerNov 6, 2025Current reportSEC
6-K · Report of a foreign issuerNov 5, 2025Current reportSEC
IMM-529 IND approved by FDANov 5, 2025Other filingsASX
Clinical Trial UpdateOct 30, 2025Operations updateASX
6-K · Report of a foreign issuerOct 30, 2025Current reportSEC
6-K · Report of a foreign issuerOct 27, 2025Current reportSEC
Immuron launch PROIBS for IBSOct 23, 2025Operations updateASX
6-K · Report of a foreign issuerOct 23, 2025Current reportSEC
6-K · Report of a foreign issuerOct 22, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
6-K · Report of a foreign issuerOct 17, 2025Current reportSEC
6-K · Report of a foreign issuerOct 14, 2025Current reportSEC
6-K · Report of a foreign issuerOct 10, 2025Current reportSEC
6-K · Report of a foreign issuerOct 7, 2025Current reportSEC
424B5 · ProspectusOct 3, 2025Offer documentSEC
6-K · Report of a foreign issuerOct 3, 2025Current reportSEC
6-K · Report of a foreign issuerOct 1, 2025Current reportSEC
6-K · Report of a foreign issuerSep 30, 2025Current reportSEC
6-K · Report of a foreign issuerSep 25, 2025Current reportSEC
20-F · Annual reportSep 25, 2025Annual reportSEC
6-K · Report of a foreign issuerSep 16, 2025Current reportSEC
6-K · Report of a foreign issuerSep 2, 2025Current reportSEC
FY25 Results PresentationAug 28, 2025Other filingsASX
Appendix 4E Preliminary Final ReportAug 28, 2025ResultsASX
6-K · Report of a foreign issuerAug 26, 2025Current reportSEC
6-K · Report of a foreign issuerAug 15, 2025Current reportSEC
6-K · Report of a foreign issuerAug 13, 2025Current reportSEC
6-K · Report of a foreign issuerJul 21, 2025Current reportSEC
6-K · Report of a foreign issuerJul 18, 2025Current reportSEC
6-K · Report of a foreign issuerJul 17, 2025Current reportSEC
6-K · Report of a foreign issuerJul 17, 2025Current reportSEC
FY25 global sales exceed projection, up 49% on prior yearJul 16, 2025ResultsASX
6-K · Report of a foreign issuerJun 4, 2025Current reportSEC
6-K · Report of a foreign issuerMay 30, 2025Current reportSEC
6-K · Report of a foreign issuerApr 11, 2025Current reportSEC
6-K · Report of a foreign issuerApr 10, 2025Current reportSEC
Immuron Travelan highest sales in historyApr 10, 2025ResultsASX
6-K · Report of a foreign issuerMar 7, 2025Current reportSEC
6-K · Report of a foreign issuerMar 5, 2025Current reportSEC
IMC and Calmino to treat Irritable Bowel Syndrome (IBS)Mar 4, 2025Other filingsASX
6-K · Report of a foreign issuerFeb 28, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2025Current reportSEC
6-K · Report of a foreign issuerJan 17, 2025Current reportSEC
Immuron Travelan continued strong sales growthJan 16, 2025ResultsASX
6-K · Report of a foreign issuerJan 15, 2025Current reportSEC
6-K · Report of a foreign issuerJan 14, 2025Current reportSEC
Immuron Announces Travelan Clinical Trial UpdateJan 14, 2025Operations updateASX
6-K · Report of a foreign issuerJan 10, 2025Current reportSEC
6-K · Report of a foreign issuerJan 8, 2025Current reportSEC
6-K · Report of a foreign issuerDec 10, 2024Current reportSEC
6-K · Report of a foreign issuerNov 22, 2024Current reportSEC
6-K · Report of a foreign issuerNov 18, 2024Current reportSEC
6-K · Report of a foreign issuerNov 14, 2024Current reportSEC
6-K · Report of a foreign issuerOct 29, 2024Current reportSEC
6-K · Report of a foreign issuerOct 18, 2024Current reportSEC
6-K · Report of a foreign issuerOct 16, 2024Current reportSEC
6-K · Report of a foreign issuerOct 15, 2024Current reportSEC
6-K · Report of a foreign issuerOct 8, 2024Current reportSEC
NMRC Reports Results for Campylobacter Clinical StudyOct 4, 2024ResultsASX
6-K · Report of a foreign issuerOct 4, 2024Current reportSEC
Trading HaltOct 2, 2024Trading halt or suspensionASX
20-F · Annual reportOct 1, 2024Annual reportSEC
6-K · Report of a foreign issuerSep 26, 2024Current reportSEC
6-K · Report of a foreign issuerSep 9, 2024Current reportSEC
6-K · Report of a foreign issuerSep 5, 2024Current reportSEC
Immuron Plans Phase 2 Trial for IMM-529 following FDA reviewSep 5, 2024Other filingsASX
Appendix 4E and Preliminary Final ReportAug 30, 2024ResultsASX
6-K · Report of a foreign issuerAug 21, 2024Current reportSEC
6-K · Report of a foreign issuerAug 16, 2024Current reportSEC
6-K · Report of a foreign issuerAug 8, 2024Current reportSEC
6-K · Report of a foreign issuerAug 7, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveJul 22, 2024Other filingsSEC
6-K · Report of a foreign issuerJul 18, 2024Current reportSEC
CORRESP · Letter to the SECJul 18, 2024Other filingsSEC
6-K · Report of a foreign issuerJul 15, 2024Current reportSEC
Immuron Travelan record sales globally, Australia and USAJul 14, 2024ResultsASX
6-K · Report of a foreign issuerJul 9, 2024Current reportSEC
UPLOAD · Letter from the SECJul 8, 2024Other filingsSEC
6-K · Report of a foreign issuerJul 5, 2024Current reportSEC
6-K · Report of a foreign issuerJul 3, 2024Current reportSEC
F-3 · Registration statementJul 2, 2024Offer documentSEC
6-K · Report of a foreign issuerJul 2, 2024Current reportSEC
IMM-529 pre-IND FDA filingJul 1, 2024Other filingsASX
6-K · Report of a foreign issuerJun 5, 2024Current reportSEC
6-K · Report of a foreign issuerMay 31, 2024Current reportSEC
6-K/A · Report of a foreign issuer, amendedMay 24, 2024Current reportSEC
6-K · Report of a foreign issuerMay 3, 2024Current reportSEC
6-K · Report of a foreign issuerApr 23, 2024Current reportSEC
6-K · Report of a foreign issuerApr 15, 2024Current reportSEC
6-K · Report of a foreign issuerApr 10, 2024Current reportSEC
Immuron Travelan sales continued strong growthApr 9, 2024ResultsASX
6-K · Report of a foreign issuerMar 14, 2024Current reportSEC
6-K · Report of a foreign issuerMar 7, 2024Current reportSEC
Travelan to progress to Phase 3 Clinical Trials in the USMar 6, 2024Operations updateASX
6-K · Report of a foreign issuerMar 4, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 21, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 13, 2024Current reportSEC
Immuron achieves record Travelan salesFeb 12, 2024ResultsASX
6-K · Report of a foreign issuerFeb 8, 2024Current reportSEC
6-K · Report of a foreign issuerJan 16, 2024Current reportSEC
Immuron achieves record half yearly Travelan salesJan 15, 2024ResultsASX
6-K · Report of a foreign issuerDec 22, 2023Current reportSEC
6-K · Report of a foreign issuerDec 4, 2023Current reportSEC
First Patients Enrolled in Campylobacter Clinical StudyDec 4, 2023Operations updateASX
6-K · Report of a foreign issuerNov 28, 2023Current reportSEC
6-K · Report of a foreign issuerNov 22, 2023Current reportSEC
6-K · Report of a foreign issuerNov 21, 2023Current reportSEC
6-K · Report of a foreign issuerNov 13, 2023Current reportSEC
6-K · Report of a foreign issuerOct 30, 2023Current reportSEC
6-K · Report of a foreign issuerOct 23, 2023Current reportSEC
6-K · Report of a foreign issuerOct 18, 2023Current reportSEC
6-K · Report of a foreign issuerOct 11, 2023Current reportSEC
Immuron achieves record quarterly Travelan salesOct 11, 2023ResultsASX
6-K · Report of a foreign issuerOct 3, 2023Current reportSEC
6-K · Report of a foreign issuerSep 28, 2023Current reportSEC
20-F · Annual reportSep 28, 2023Annual reportSEC
6-K · Report of a foreign issuerSep 13, 2023Current reportSEC
Immuron achieves record monthly Travelan salesSep 13, 2023ResultsASX

This page holds 200 of 604 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Immuron Limited’s releases

Common shares
322,848,081
Fully diluted
322,848,081

Fully diluted

LineShares
Common shares322,848,081

Share count over time

CountShares
Nov 22, 2026322,848,081

Open Cap table

Shareholders

HolderSharesValueAs of
BNP Paribas49,549US$57,477Sep 30, 2026
Hrt Financial LP33,396US$38,000Sep 30, 2026
Jane Street33,255US$38,576Sep 30, 2026
UBS22,512US$26,114Sep 30, 2026
Citadel14,690US$17,040Sep 30, 2026
Rhumbline Advisers3,835US$4,448Sep 30, 2026
RBC160Sep 30, 2026
Caitong International Asset Management Co., Ltd28US$32Sep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Aaron Laurita
Other companies: Radiopharm Theranostics Limited (Chief Financial Officer · Since at least Mar 18, 2026)
Chief Financial Officer · Since at least Feb 9, 2026
Daniel PollockNon-Executive Director – LL.B. Dip.L.P. · Since at least Mar 18, 2026
Flavio PalumboChief Commercial Officer · Since at least Mar 18, 2026
Jeannette Anne JoughinDirector · Since at least Mar 18, 2026
Jeannie JoughinNon-Executive Director – BSc (Hons), PhD, MAICD · Since at least Nov 5, 2026
Jerry KanellosChief Scientific Officer · Since at least Mar 18, 2026
Jerry KanellosChief Scientific Officer · Since at least Nov 4, 2026
Joanne CaseyResearch & Development Manager · Since at least Nov 5, 2026
Olga SmejkalovaCompany Secretary · Since at least Nov 5, 2026
Paul BrennanChairman · Since at least Mar 18, 2026
All 13 people
PersonSeat
Ravi SavarirayanNon-Executive Director · Since at least Mar 18, 2026
Steven George LydeamoreChief Executive Officer · Since at least Mar 18, 2026
Steven LydeamoreChief Executive Officer · Since at least Oct 28, 2026

Open People

Log in to ask 6ix AI your own questions about Immuron Limited.